Literature DB >> 26992862

Efficacy of Group Motivational Interviewing in the Degree of Drug Craving in the Addicts Under the Methadone Maintenance Treatment (MMT) in South East of Iran.

Ali Navidian1, Fatihe Kermansaravi1, Ebrahim Ebrahimi Tabas2, Farshid Saeedinezhad3.   

Abstract

BACKGROUND: Craving is one of the important factors having an effective role in the addiction relapse. As an important factor in the therapy failure, this clinical phenomenon has to be diagnosed and treated.
OBJECTIVE: The present research aimed at determining the efficacy of group motivational interviewing in the degree of drug craving in the addicts under the Methadone Maintenance Treatment (MMT).
METHOD: This is a quasi-experimental study carried out on 100 addicted men (aged 18-50 years), who were under the MMT in a drug abstinence clinic affiliated with University of Medical Sciences (Iran) in the second half of 2014. The research sample was selected by the availability criteria based on the inclusion and exclusion criteria, and upon matching, it was divided randomly into two groups of 50 (control and treatment). The treatment group first received 5 sessions of group motivational counseling; then it entered the therapy process. The control group received the usual treatment of the drug abstinence clinic. To assess the drug craving degree (in the pretest, 2, 6 and 12 months after the abstinence), the Visual Cue-induced Craving Task, scored 0 to 100, was used. The data were analyzed by the descriptive statistics through independent t-test, and repeated measures analysis of variance.
RESULTS: The means of craving degrees in the control group, 2, 6 and 12 months after the abstinence (73.28 ± 7.52, 65.83 ± 6.69 and 61.25±5.17, respectively) were significantly (p=0.0001) higher than those in the treatment group (68.94 ± 10.53, 40.48 ± 11.78 and 32.51 ± 9.00). Moreover, the mean of retention in the treatment was 9.24 ± 2.45 months in the treatment group that was significantly (p=0.001) higher than the 4.88 ± 3.65 months of retention in the control group.
CONCLUSION: The research results support the fact that motivational interviewing decreases the degree of drug craving, and increases the probability of the addicts' retention in long-term therapeutic abstinence programs. Therefore, the use of such an approach as a pretreatment and a complementary therapy in changing health behaviors is recommended.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26992862     DOI: 10.1016/j.apnu.2015.08.002

Source DB:  PubMed          Journal:  Arch Psychiatr Nurs        ISSN: 0883-9417            Impact factor:   2.218


  4 in total

1.  Characteristics and Correlates of Psychiatric Problems in Wives of Men with Substance-related Disorders, Kermanshah, Iran.

Authors:  Toraj Ahmadi Juibari; Behrouz Behrouz; Mari Attaie; Vahid Farnia; Sanobar Golshani; Masuod Moradi; Mostafa Alikhani
Journal:  Oman Med J       Date:  2018-11

2.  Randomized controlled trial of group motivational interviewing for veterans with substance use disorders.

Authors:  Elizabeth J Santa Ana; Steven D LaRowe; Mulugeta Gebregziabher; Antonio A Morgan-Lopez; Kayla Lamb; Katherine A Beavis; Kinfe Bishu; Steve Martino
Journal:  Drug Alcohol Depend       Date:  2021-04-20       Impact factor: 4.852

3.  Effects of a group activity-based motivational enhancement therapy program on social media addictive behaviors among junior high school students in Thailand: a cluster randomized trial.

Authors:  Mereerat Manwong; Vitool Lohsoonthorn; Thanvaruj Booranasuksakul; Anun Chaikoolvatana
Journal:  Psychol Res Behav Manag       Date:  2018-08-31

4.  A full-factorial randomized controlled trial of adjunct couples HIV testing and counseling components addressing drug use and communication skills among sexual minority male couples.

Authors:  Tyrel J Starks; Kory D Kyre; Christine B Cowles; Juan Castiblanco; Catherine Washington; Jayelin N Parker; Erin M Kahle; Rob Stephenson
Journal:  BMC Public Health       Date:  2021-11-24       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.